All News

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen. Read more… https://t.co/swXZ4FxB33 #RheumNow #medtwitter https://t.co/zqfd9IPeEf

Links:

Dr. John Cush RheumNow ( View Tweet)
Pills.JIA_.png

Different Regimens but Equal Outcomes in Polyarticular JIA

d Jack Cush, MD

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.

Read Article
NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD

Links:

Dr. John Cush RheumNow ( View Tweet)

Cancer.risk_.jpg

Lymphoma in RA: Disease Activity Matters

d MedPage Today

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for lymphoma, with an odds ratio of 2.09 (95% CI 1.41-3.38), according to Gaetane Nocturne, MD, of Hôpital Bicêtre in Ile-de-France, and colleagues.

Read Article
MMWR: COVID-19–hospitalization rates in kids & adolescents rose 5-fold late June–mid-Aug 2021 (w/ rise of Delta variant). Hospitalization rates were 10 times higher among unvaccinated than fully vaccinated adolescents. https://t.co/Qt5lj3Ycxb

Links:

Dr. John Cush RheumNow ( View Tweet)

500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA

Links:

Dr. John Cush RheumNow ( View Tweet)
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RC3Cph https://t.co/jMsuUM9lWy

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

d Jack Cush, MD

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

In the week ending 8/12: 👧🏽121,427 pediatric #COVID19 cases (14.4% of all cases, 49 states) 🏥452 pediatric hospitalizations (24 states reporting) 💀7 pediatric deaths (43 states reporting) One death is too many.

Shematologist, MD acweyand ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
85 rheumatic kids RTX treated - New hypogammaglobulinemia in 27% w/in 18 mos AND 26% w/ infections (half being serious infx). Prior pulse steriods ups risk of inx (OR 15.3) and hypogamma (OR 3.9). Hypogamm predicts risk of SIE (OR 7.9)

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

d Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
tkr_0.JPG

Delays in Joint Replacement as JIA Patients Reach Adulthood

d Jack Cush, MD

A retrospective cohort study examined the need for joint replacement surgery in juvenile idiopathic arthritis (JIA) and showed there has been a trend to delay arthroplasty over time. The JIA category, year of implant, and presence of complications significantly affected implant survivorship.

Read Article
The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU

Links:

Dr. John Cush RheumNow ( View Tweet)

JIA_0.jpg

Arthritis as a Harbinger of Pediatric Cancer

d Jack Cush, MD

Lancet Rheumatology has published a cohort analysis showing that a small but significant subset of children presenting with arthralgia or arthritis may have a pediatric malignancy.

Read Article
Septic arthritis MIMICs (all presenting as acute monoarthritis) - consider: cellulitis, bursitis, abscess, osteonecrosis, gout, pseudogout, Lyme, Osteomyelitis, reactive arthritis, Lyme disease,, Rheumatoid arthritis, & Transient synovitis (kids) https://t.co/uNirAcoBds

Links:

Dr. John Cush RheumNow ( View Tweet)

2020 Year Review

ICYMI: 2020 Rheumatology Year in Review

d Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/010QYkOO7E

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.